ISSN: 1859 - 2872
Allopurinol allergy: Prevention effects
Main Article Content
Keywords
Abstract
Allopurinol is very effective at reducing uric acid levels, commonly used to treat Gout, recurrent kidney stones, and tumor lysis syndrome in cancer patient during treatment. However, it is one of the leading drugs causing severe drug-induced skin damage with a high mortality rate. There are many factors affecting the risk of allopurinol allergy in patients. HLA-B*5801 screening in Asian, or African have been proven to be effective. When positive with this gene, patient will need to use alternative drugs or undergo drug desensitization protocol before treatment. It is an effective and less expensive method compared to treating patients after drug allergies happen. Changing the dose, based on the creatinine clearance plus the restriction on methods that increase the risk of drug allergies such as the use of diuretics, etc., is also one of the allopurinol drug allergy prevention methods. Use of drug allergy diagnostic tests before medication also limits the risk of allopurinol allergy.
Article Details
References
2. Marianne L, Carlo M, Benedetta T et al (2018) Current perspectives on stevens-johnson syndrome and toxic epidermal necrolysis. Clin Rev Allergy Immunol 54(1): 147-176.
3. Kim S, Newcomb C, Margolis D, Roy J, Hennessy S (2013) Severe cutaneous reactions requiring hospitalization in allopurinol initiators: A population-based cohort study. Arthritis Care Res 65: 57884.
4. Ramasamy S, Korb-Wells C, Kannangara D et al (2013) Allopurinol hypersensitivity: A systematic review of all published cases. Drug Saf 36: 953-980.
5. Hung S, Chung W, Liou L et al (2005) HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA. 102: 41349.
6. Tassaneeyakul W, Jantararoungtong T, Chen P et al (2009) Strong association between HLA-B*5801 and allopurinol induced Stevens-johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics 19: 704-709.
7. Park DJ, Kang JH, Lee JW et al (2015) Cost-effectiveness analysis of HLA-B5801 genotyping in the treatment of gout patients with chronic renal insufficiency in Korea. Arthritis Care Res 67: 280-287.
8. Lonjou C, Borot N, Sekula P et al (2008) A European study of HLA-B in StevensJohnson syndrome and toxic epidermal necrolysis related to five high risk drugs. Pharmacogenet Genomics 18: 99-107.
9. John DF, Nicola D, Ted M et al (2020) 2020 American college of rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken) 72(6): 744-760.
10. Ko T, Tsai C, Chen S et al (2015) Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: National prospective cohort study. BMJ Case Reports 351: 4848.
11. Zhu Y, Pandya B, Choi H (2012) Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med 125: 679-687.
12. Lisa KS, Muray LB (2018) How to prevent allopurinol hypersensitivity reaction? Rheumatology 57: 35-41.
Article Sidebar
